Leap Therapeutics, Inc. is a biopharmaceutical company. Co. is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. We show 33 historical shares outstanding datapoints in our LPTX shares outstanding history coverage, used to compute LPTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing LPTX market cap history over the course of time is important for investors
interested in comparing LPTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of LPTX versus a peer is one thing; comparing
LPTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like LPTX can fluctuate over the course of history.
With this page we aim to empower investors researching LPTX by allowing them to research the LPTX market cap history. |
Free LPTX Email Alerts:
Video: The Importance of Market Cap
